![]() SUSVIMO (ranibizumab injection) is a prescription medicine used to treat adults with neovascular wet AMD twice-yearly vs. Patients with wet AMD are treated with frequent intraocular injections of Vascular Endothelial Growth Factor (VEGF) administered by a Retina Specialist in the office. If the disease is discovered in its early stages, treatments can help prevent the vision loss from both dry and wet AMD. If AMD advances, it becomes the more vision threatening “wet” AMD, which is called “wet” due to blood vessel growth and leakage. Early in the disease in patients with “dry” AMD, there are often minimal symptoms. It is the leading cause of blindness in people over the age of 60. John Kitchens.ĪMD is a medical condition which may result in blurred or no vision in the center of the vision. It is truly a groundbreaking accomplishment that will change the way we treat people with this condition,” said Dr. Having an option for patients that can dramatically reduce the number of office visits and injections for patients and their families cannot be understated. “This is a really big day for patients with wet age-related macular degeneration. Since the approval date, there has been extensive coordination between the Lexington Surgery Center and Cardinal Health, their pharmaceutical distribution partner, to allow for the first patient to potentially benefit from this new sight saving technique. In October 2021 the FDA approved Genentech's SUSVIMO for AMD, a common and potentially blinding eye disease that is currently treated with monthly injections. For several years, the doctors at Retina Associates of Kentucky have been active in clinical trials for SUSVIMO, the first and only sustained release treatment for Wet Age-related Macular Degeneration (AMD). On November 30th, 2021, John Kitchens, MD, from Retina Associates of Kentucky, was the first in the world to surgically implant FDA approved SUSVIMO at the Lexington Surgery Center in Lexington, Kentucky. John Kitchens FIRST IN THE WORLD to Implant Genentech’s SUSVIMO Following FDA Approval You can also visit us to check out our locations and refer a patient at our website, Stone, Purkiss and our clinical team are excited to welcome our patients in our new Elizabethtown office!įor more information about the new Elizabethtown location or to schedule an appointment you may reach the Scheduling Department at (800) 627-2020. We will begin seeing patients in our new office on December 22nd.ĭrs. Our new office is conveniently located off of I-65, near the Kroger and directly across the street from the Post Office at 2935 Dolphin Drive, Building 300, Suite 302A. We will continue to service Bardstown and other surrounding area patients in Elizabethtown, Danville, Louisville and Somerset. Retina Associates of Kentucky is excited to announce that we are relocating our Bardstown office to Elizabethtown to better serve our growing population of Central and Western Kentucky patients. ![]() Patients using Latisse can expect to experience longer, fuller, and darker eyelashes in as little as four weeks, with full results in sixteen weeks.Retina Associates proudly announces their new office location in Elizabethtown, Kentucky Opening December 22, 2021! Available only through prescription, Latisse is a once-daily treatment applied to the base of the upper eyelashes. Latisse is a breakthrough treatment to enhance eyelash prominence by increasing length, thickness, and darkness. Hypotrichosis is another name for having inadequate or not enough eyelashes. Latisse® is the first and only FDA approved treatment for hypotrichosis of the eyelashes. We pride ourselves in being caring and compassionate while providing individualized care for our patients! We Now Offer Latisse®!
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |